Table 3.
The bidirectional MR analysis of decaffeinated coffee consumption and neuropsychiatric traits.
| Exposure-outcome | No. of SNP | IVW | MR egger | ||||||
|---|---|---|---|---|---|---|---|---|---|
| β | P-Value | Q-Value | P-Value | Q-Value | P-Value | Intercept | P-Value | ||
| DCC-AD | 31 | −0.015 | 0.320 | 35.275 | 0.233 | 35.251 | 0.196 | 0.000 | 0.888 |
| DCC-ALS | 31 | 0.140 | 0.233 | 36.680 | 0.187 | 35.789 | 0.180 | 0.011 | 0.403 |
| DCC-ADHD | 27 | 0.059 | 0.553 | 33.290 | 0.154 | 32.803 | 0.136 | 0.006 | 0.548 |
| DCC-BIP | 31 | 0.005 | 0.949 | 26.947 | 0.626 | 26.278 | 0.611 | 0.007 | 0.420 |
| DCC-AN | 24 | −0.001 | 0.995 | 29.425 | 0.167 | 28.962 | 0.146 | −0.007 | 0.559 |
| DCC-AUDIT_T | 27 | 0.027 | 0.003 | 35.391 | 0.103 | 33.778 | 0.113 | −0.001 | 0.285 |
| DCC-AUDIT_C | 28 | 0.014 | 0.057 | 29.985 | 0.315 | 29.357 | 0.295 | −0.001 | 0.462 |
| DCC-AUDIT_P | 26 | 0.018 | 0.034 | 37.630 | 0.050 | 37.621 | 0.038 | 0.000 | 0.940 |
| DCC-Insomnia | 25 | −0.040 | 0.303 | 32.412 | 0.117 | 32.411 | 0.092 | 0.000 | 0.983 |
| DCC-LCU* | 28 | 0.241 | 7.63E-04 | 30.858 | 0.277 | 30.644 | 0.242 | 0.003 | 0.673 |
| DCC-MDD* | 27 | −0.107 | 9.06E-05 | 21.474 | 0.717 | 21.175 | 0.683 | −0.002 | 0.590 |
| DCC-Neuroticism | 23 | −0.041 | 0.109 | 59.736 | 0.000 | 58.145 | 0.000 | −0.002 | 0.457 |
| DCC-SCZ | 11 | −0.006 | 0.952 | 4.504 | 0.922 | 4.310 | 0.890 | 0.006 | 0.670 |
| AD-DCC | 76 | 0.002 | 0.956 | 92.985 | 0.078 | 92.813 | 0.069 | 0.001 | 0.712 |
| ALS-DCC | 21 | −0.005 | 0.769 | 27.183 | 0.130 | 27.063 | 0.103 | 0.002 | 0.774 |
| ADHD-DCC | 86 | −0.012 | 0.267 | 100.358 | 0.122 | 100.294 | 0.108 | 0.001 | 0.817 |
| BIP-DCC | 138 | 0.008 | 0.324 | 149.295 | 0.223 | 149.119 | 0.209 | −0.001 | 0.689 |
| AN-DCC | 77 | −0.015 | 0.204 | 88.495 | 0.155 | 87.278 | 0.157 | −0.003 | 0.310 |
| AUDIT_T-DCC* | 62 | 0.603 | 1.67E-05 | 65.759 | 0.316 | 64.366 | 0.326 | 0.004 | 0.259 |
| AUDIT_C-DCC* | 51 | 0.589 | 5.09E-04 | 55.809 | 0.266 | 51.828 | 0.364 | 0.006 | 0.058 |
| AUDIT_P-DCC | 47 | 0.818 | 0.003 | 105.863 | 0.000 | 105.733 | 0.000 | −0.001 | 0.816 |
| Insomnia-DCC* | 109 | −0.099 | 1.51E-04 | 130.942 | 0.066 | 130.848 | 0.058 | −0.001 | 0.782 |
| LCU-DCC | 64 | 0.019 | 0.171 | 59.735 | 0.593 | 54.238 | 0.748 | 0.005 | 0.022 |
| MDD-DCC* | 212 | −0.077 | 6.02E-04 | 272.908 | 0.003 | 272.601 | 0.002 | −0.001 | 0.627 |
| Neuroticism-DCC | 294 | −0.088 | 0.008 | 354.888 | 0.008 | 353.747 | 0.008 | 0.002 | 0.333 |
| SCZ-DCC | 323 | 0.015 | 0.050 | 393.112 | 0.004 | 387.319 | 0.007 | 0.004 | 0.029 |
IVW, inverse-variance weighted; DCC, decaffeinated coffee consumption; AD, Alzheimer's disease; ALS, Amyotrophic lateral sclerosis; ADHD, Attention deficit and hyperactivity disorder; BIP, bipolar disorder; AN, Anorexia nervosa; MDD, major depression disorder; LCU, lifetime cannabis use; SCZ, Schizophrenia; AUDIT_T, Alcohol use disorder identification test total score; AUDIT_C, alcohol consumption component of alcohol use disorder identification test item 1–3 score; AUDIT_P, dependence and hazardous-use component of alcohol use disorder identification test item 4–10 score.
*Significant causality after Bonferroni correction (P <0.05/26 traits = 0.0019).